- Home
- CALC
CALC
CalciMedica Inc.
as 11-14-2024 3:31pm EST
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 44.7M | IPO Year: | N/A |
| Target Price: | $19.50 | AVG Volume (30 days): | 89.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.68 - $8.38 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of CalciMedica Inc. (CALC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Nov 1 '24 | Buy | $3.75 | 53,333 | $199,998.75 | 164,706 | |
| WILSON ROBERT N | CALC | Director | Nov 1 '24 | Buy | $3.75 | 53,333 | $199,998.75 | 417,529 | |
| Leheny A. Rachel | CALC | CHIEF EXECUTIVE OFFICER | Aug 27 '24 | Buy | $4.19 | 1,000 | $4,189.80 | 110,926 | |
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Aug 23 '24 | Buy | $3.57 | 5,000 | $17,867.00 | 164,706 | |
| WILSON ROBERT N | CALC | Director | Aug 23 '24 | Buy | $3.72 | 54,000 | $200,826.00 | 417,529 | |
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Aug 21 '24 | Buy | $4.04 | 5,000 | $20,200.00 | 164,706 |
Latest CalciMedica Inc. News
CALC Breaking Stock News: Dive into CALC Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
PR Newswire
8 days ago
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
Argus Research
9 days ago
Daily – Vickers Top Buyers & Sellers for 11/06/2024
PR Newswire
15 days ago
CalciMedica Announces Pricing of Public Offering of Common Stock
PR Newswire
15 days ago
CalciMedica Announces Proposed Public Offering of Common Stock
PR Newswire
16 days ago
CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
PR Newswire
17 days ago
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
PR Newswire
a month ago
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
Compare CALC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CALC CalciMedica Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.